Dr. Johannes Hankowitz
Partnerschaftsgesellschaft Dr. Bramlage & Dr. Hankowitz
Dr. Hankowitz studied pharmacy and philosophy with a focus on ethics, scientific theory, and structural research at the University of Münster and the Max Planck Institute for Biochemistry in Martinsried, near Munich, Germany. His doctoral dissertation, completed at the Institute for Clinical Chemistry, was on the topic of the effects of drugs on signal transduction in atherogenic processes. He subsequently worked as a research associate at the Regensburg University Hospital, in the Institute for Clinical Chemistry, focusing on immunology and oncology.
During his work, Dr Hankowitz received a Master’s degree in European Studies (M.E.S.) from the RWTH Aachen University, with a legal thesis on pharmacovigilance. He then moved to Sanofi Winthrop, working in the field of antithrombotics. He later became Medical Director of Sanofi-Synthelabo in the areas of thrombosis, cardiology, and the CNS, and Director of Medicine and Marketing for thrombosis and cardiology. Following this, he was the Head of Medicine and Pharmacy at Winthrop Arzneimittel GmbH, and was a company Director. Dr Hankowitz has experience in all aspects relevant to the AMG (German Medicinal Products Act), including data management, risk categorisation, and controlled drugs; being a Qualified Person; and marketing management.
Mr. Hankowitz is owner and editor of AMNOG-monitor – an interactive analysis tool for evaluation of all G-BA resolutions according to §35a SGB V. He is an expert of early benefit assessment in Germany including phase III clinical programme, Joint Scientific Advise (BfArM & G-BA), strategic consulting & compilation of benefit dossiers and price negotiations.